Found: 86
Select item for more details and to access through your institution.
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01135-2
- By:
- Publication type:
- Article
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00888-6
- By:
- Publication type:
- Article
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00883-x
- By:
- Publication type:
- Article
Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00866-y
- By:
- Publication type:
- Article
Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?
- Published in:
- 1989
- By:
- Publication type:
- journal article
The NASN Book Store.
- Published in:
- NASN School Nurse, 2002, v. 17, n. 4, p. 6, doi. 10.1177/104747570201700403
- By:
- Publication type:
- Article
Focus on Masn Membership.
- Published in:
- NASN School Nurse, 2002, v. 17, n. 1, p. 5, doi. 10.1177/104747570201700101
- By:
- Publication type:
- Article
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
- Published in:
- Current Oncology, 2022, v. 29, n. 3, p. 1575, doi. 10.3390/curroncol29030132
- By:
- Publication type:
- Article
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 93, doi. 10.1111/bjh.18172
- By:
- Publication type:
- Article
The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 5, p. e52, doi. 10.1111/bjh.17946
- By:
- Publication type:
- Article
Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 532, doi. 10.1111/bjh.17350
- By:
- Publication type:
- Article
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 5, p. e117, doi. 10.1111/bjh.15946
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 896, doi. 10.1111/bjh.14787
- By:
- Publication type:
- Article
Thalidomide-prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 4, p. 511, doi. 10.1111/bjh.13176
- By:
- Publication type:
- Article
Phase I- II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 1, p. 46, doi. 10.1111/bjh.13100
- By:
- Publication type:
- Article
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 563, doi. 10.1111/bjh.13004
- By:
- Publication type:
- Article
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 5, p. 1, doi. 10.1111/bjh.13004
- By:
- Publication type:
- Article
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 5, p. 722, doi. 10.1111/bjh.12673
- By:
- Publication type:
- Article
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 4, p. 483, doi. 10.1111/bjh.12414
- By:
- Publication type:
- Article
D(T) PACE as salvage therapy for aggressive or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 6, p. 802, doi. 10.1111/bjh.12325
- By:
- Publication type:
- Article
Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3mL per injection site.
- Published in:
- Journal of Oncology Pharmacy Practice, 2015, v. 21, n. 4, p. 285, doi. 10.1177/1078155214533367
- By:
- Publication type:
- Article
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. 552, doi. 10.1002/ajh.26147
- By:
- Publication type:
- Article
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 5, p. 815, doi. 10.1111/ejh.14082
- By:
- Publication type:
- Article
Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 3, p. 204, doi. 10.1111/ejh.13726
- By:
- Publication type:
- Article
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 416, doi. 10.1111/ejh.13678
- By:
- Publication type:
- Article
A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 3, p. 333, doi. 10.1111/ejh.13671
- By:
- Publication type:
- Article
The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 5, p. 673, doi. 10.1111/ejh.13596
- By:
- Publication type:
- Article
Phase III Studies in Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, p. S33
- By:
- Publication type:
- Article
Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 36
- By:
- Publication type:
- Article
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing.
- Published in:
- Life Science Alliance, 2023, v. 6, n. 1, p. 1, doi. 10.26508/lsa.202201543
- By:
- Publication type:
- Article
How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership.
- Published in:
- Research Involvement & Engagement, 2023, v. 9, n. 1, p. 1, doi. 10.1186/s40900-023-00476-9
- By:
- Publication type:
- Article
Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 4357, doi. 10.1002/cam4.5245
- By:
- Publication type:
- Article
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 1, p. 3, doi. 10.1002/cam4.799
- By:
- Publication type:
- Article
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.826342
- By:
- Publication type:
- Article
Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 162, doi. 10.1016/j.clml.2012.09.003
- By:
- Publication type:
- Article
Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 1, p. 19, doi. 10.1016/j.clml.2012.08.009
- By:
- Publication type:
- Article
Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 1, p. 25, doi. 10.1016/j.clml.2012.08.008
- By:
- Publication type:
- Article
Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 6, p. 458, doi. 10.3816/CLML.2010.n.078
- By:
- Publication type:
- Article
Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus.
- Published in:
- Advances in Hematology, 2012, p. 1, doi. 10.1155/2012/621958
- By:
- Publication type:
- Article
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
- Published in:
- European Journal of Haematology, 2015, v. 95, n. 4, p. 316, doi. 10.1111/ejh.12491
- By:
- Publication type:
- Article
The Impact of CD34<sup>+</sup> Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 11, p. 850, doi. 10.1016/j.clml.2023.07.014
- By:
- Publication type:
- Article
A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 484, doi. 10.1016/j.clml.2023.03.006
- By:
- Publication type:
- Article
Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 2, p. e97, doi. 10.1016/j.clml.2022.11.007
- By:
- Publication type:
- Article
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 608, doi. 10.1016/j.clml.2022.03.002
- By:
- Publication type:
- Article
Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 12, p. e946, doi. 10.1016/j.clml.2021.07.003
- By:
- Publication type:
- Article
P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S162, doi. 10.1016/S2152-2650(21)02349-1
- By:
- Publication type:
- Article
P-189: Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma (MM-014 phase 2 trial): a subanalysis of patients previously treated with lenalidomide and a proteasome inhibitor.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S141, doi. 10.1016/S2152-2650(21)02316-8
- By:
- Publication type:
- Article
P-019: Real-world treatment patterns, clinical outcomes, and healthcare resource utilization of individuals with light chain (AL) amyloidosis in Alberta, Canada: a population-based study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S49, doi. 10.1016/S2152-2650(21)02153-4
- By:
- Publication type:
- Article
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
- By:
- Publication type:
- Article
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
- Published in:
- 2020
- By:
- Publication type:
- journal article